The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats
Launched by UNIVERSITY OF BRITISH COLUMBIA · Feb 26, 2008
Trial Information
Current as of September 13, 2025
Completed
Keywords
ClinConnect Summary
1. Purpose: to examine in detail the effect of droperidol and ondansetron on Tp-e (an ECG measure of dispersion of repolarization); to search with maximum statistical power for a difference in this parameter before and after exposure to this widely used anaesthetic. To investigate the nature of any dose-response relationship between propofol and mean QTc and Tp-e intervals.
2. Hypotheses: 1. H0: mean pre-operative Tp-e = mean intra-operative Tp-e within each group vs. H1: mean pre-operative Tp-e ≠ mean intra-operative Tp-e within each group. 2. H0: mean intra-operative Tp-e group 1 = mean i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy children (ASA I-II) undergoing procedures that require general anesthesia without pre-medication.
- Exclusion Criteria:
- • Children with long QT syndrome, a family history of long QT syndrome or taking medication that is known to prolong the QT interval.
- • IV access unobtainable pre-operatively.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Simon Whyte, MD
Principal Investigator
University of British Columbia
Mark Ansermino, MD
Study Director
University of British Columbia
Shubhayan Sanatani, MD
Study Director
University of British Columbia
Joanne Lim
Study Director
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials